Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as ixabepilone, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving lapatinib together with ixabepilone may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib given
together with ixabepilone in treating patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Bristol-Myers Squibb Genentech, Inc. National Cancer Institute (NCI)